17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.
Level 5 - mechanism / opinion, no new human data
Trial protocol description and narrative review with no new human trial outcome data reported
PubMed 25835751 · doi:10.1016/j.maturitas.2015.02.266
What was done
This paper describes the protocol and rationale for the REPLENISH phase 3 trial, an ongoing randomized controlled trial evaluating TX-001HR (a single oral gelatin capsule combining solubilized 17β-estradiol and natural progesterone across 4 doses versus placebo) in postmenopausal women. The planned trial assesses the frequency and severity of moderate-to-severe vasomotor symptoms at 4 and 12 weeks and endometrial safety at 1 year. The authors also narratively review existing evidence comparing natural estradiol and progesterone against conjugated equine estrogens and synthetic progestins.
What was found
The abstract provides no clinical efficacy or safety outcome data from the REPLENISH trial itself, as the trial was ongoing at publication. It mentions that prior pharmacokinetic findings demonstrated similar bioavailability and safety between TX-001HR and co-administered reference estradiol tablets and micronized progesterone capsules.
Why it matters
If proven safe and effective, a combined single-capsule formulation of 17β-estradiol and micronized progesterone would provide an FDA-regulated alternative to compounded bioidentical hormone therapy that also avoids peanut oil excipients.
Limits
This publication is strictly a study protocol and literature review without empirical results or statistical findings. Participant sample size, inclusion criteria specifics, and power calculations are not reported in the abstract.
Cited by
- supports Standard pharmacy brand-name estradiol and micronized progesterone are bioidentical, whereas equine estrogens and synthetic progestins are not bioidentical.